CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
精准靶向与替代效应细胞：革新 T 细胞恶性肿瘤的 CAR 疗法
英文原题：Precision targeting and alternative effector cells: Revolutionizing CAR-based therapy for T-cell malignancies.
查看英文原题
Precision targeting and alternative effector cells: Revolutionizing CAR-based therapy for T-cell malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
T细胞恶性肿瘤具有高度异质性，并与高复发率和不良预后相关。尽管CAR-T（CAR-T）细胞治疗在复发/难治性B细胞恶性肿瘤中取得了显著成功，但其在T细胞恶性肿瘤中的应用仍然有限。关键挑战包括CAR-T 细胞、正常T细胞和恶性T细胞之间共享表面抗原表达，导致自相残杀和T细胞发育不全，以及CAR-T 制造过程中肿瘤细胞污染的风险。本综述总结了针对T细胞恶性肿瘤的CAR基础疗法的最新进展，重点关注临床转化障碍、新兴解决方案和未来方向。
展开英文摘要原文
T-cell malignancies are highly heterogeneous and associated with high relapse rate and poor prognosis. While chimeric antigen receptor-T (CAR-T) cell therapy has achieved remarkable success in relapsed or refractory B-cell malignancies, its application in T-cell malignancies remains limited.
Key challenges include shared surface antigen expression among CAR-T cells, normal T cells, and malignant T cells, leading to fratricide and T-cell aplasia, and the risk of tumor cell contamination during CAR-T manufacturing. This review summarizes recent advances in CAR-based therapies for T-cell malignancies, focusing on clinical translation barriers, emerging solutions, and future directions.
We highlight promising target antigens under preclinical and clinical investigation, as well as alternative effector platforms, including natural killer (NK) cells, NKT cells, γδ T cells, and macrophages, that hold potential as next-generation CAR-expressing cellular therapeutics.
论文信息
- 作者
- Chen Y、Gao S、Liu S、Yang P、Jing H
- 单位
- Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 49 Huayuan North Road, Haidian District, Beijing 100191, China.China
- 期刊
- Clinical and experimental immunology2026 Oct 6
- 原文标识
- PubMed 42834771 · DOI 10.1093/cei/uxag060
READING GUIDES
相关资料阅读指南
了解这条资料涉及的技术、疾病或试验登记信息，再回到原始来源核实。